Yasuyuki Komiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yasuyuki Komiyama has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Atsunori Tsuchiya
Department of Gastroenterology and Hepatology Faculty of Medicine University of Yamanashi Chuo Japan
1 shared publication- Chikara Ogawa
Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan
1 shared publication Haruhiko Kobashi
Department of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan
1 shared publicationHideki Fujii
Department of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan
1 shared publicationHideo Yoshida
Department of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan
1 shared publication- Hironori Ochi
Center for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan
1 shared publication
Latest Publications
- 11 September 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (11) , 1518-1530
Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance
Aim: Bradycardic responses frequently occur during radiofrequency ablation (RFA) and microwave ablation (MWA) for hepatocellular carcinoma (HCC), but the impact of procedural pain severity and patient‐specific factors remains unclear. This study aimed to evaluate the incidence and risk factors for bradycardic responses, focusing on procedural pain and autonomic regulation. Methods: This retrospective study included 267 patients with solitary HCC who underwent RFA or MWA between 2019 and 2024. Bradycardic responses were defined as a ≥ 30% decrease in heart rate from baseline or < 50 bpm. Patients were categorized by procedural pain severity using patient‐controlled analgesia (PCA) bolus administration. Risk factors for bradycardia were assessed by logistic regression. Results: Bradycardic responses occurred in 70 patients (26.2%). Severe procedural pain (odds ratio [OR], 2.26 and p = 0.007) and primary HCC (OR, 2.68 and p = 0.002) were independent risk factors. In patients without severe pain, absence of angiotensin II receptor blocker (ARB) use increased bradycardia risk (OR, 0.14 and p = 0.013). Most bradycardic events (61.4%) occurred within 3 min of ablation initiation. Conclusions: Bradycardic responses during RFA and MWA are common and linked to procedural pain severity and autonomic imbalance. Comprehensive management, including pain control, medication review, and addressing procedural anxiety through counseling or sedation, may reduce risks and enhance procedural safety.
- 11 September 2025
- Published by Wiley in Hepatology Research
- Vol. 55 (11) , 1518-1530
Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance
Aim: Bradycardic responses frequently occur during radiofrequency ablation (RFA) and microwave ablation (MWA) for hepatocellular carcinoma (HCC), but the impact of procedural pain severity and patient‐specific factors remains unclear. This study aimed to evaluate the incidence and risk factors for bradycardic responses, focusing on procedural pain and autonomic regulation. Methods: This retrospective study included 267 patients with solitary HCC who underwent RFA or MWA between 2019 and 2024. Bradycardic responses were defined as a ≥ 30% decrease in heart rate from baseline or < 50 bpm. Patients were categorized by procedural pain severity using patient‐controlled analgesia (PCA) bolus administration. Risk factors for bradycardia were assessed by logistic regression. Results: Bradycardic responses occurred in 70 patients (26.2%). Severe procedural pain (odds ratio [OR], 2.26 and p = 0.007) and primary HCC (OR, 2.68 and p = 0.002) were independent risk factors. In patients without severe pain, absence of angiotensin II receptor blocker (ARB) use increased bradycardia risk (OR, 0.14 and p = 0.013). Most bradycardic events (61.4%) occurred within 3 min of ablation initiation. Conclusions: Bradycardic responses during RFA and MWA are common and linked to procedural pain severity and autonomic imbalance. Comprehensive management, including pain control, medication review, and addressing procedural anxiety through counseling or sedation, may reduce risks and enhance procedural safety.
- Open Access
Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
Aim: Although pemafibrate, a selective peroxisome proliferator‐activated receptor α (PPARα) modulator primarily prescribed for hypertriglyceridemia, may improve liver function in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), its efficacy has not been sufficiently evaluated. This study aimed to assess the effect of pemafibrate on liver function in patients with MASLD using a nationwide multicenter cohort.Methods: In this nationwide multicenter study, we analyzed 352 patients diagnosed with MASLD and hypertriglyceridemia who newly initiated pemafibrate therapy. The primary outcome was the rate of ALT normalization (ALT ≤ 30 U/L). Laboratory data were collected at baseline and 3, 6, and 12 months after pemafibrate initiation, and longitudinal changes were evaluated.Results: The mean ALT levels decreased significantly from 60.1 ± 1.8 U/L at baseline to 44.9 ± 1.4, 41.6 ± 1.3, and 38.1 ± 1.3 U/L at 3, 6, and 12 months, respectively (all p < 0.001). The ALT normalization rate increased from 30.4% at baseline to 46.0%, 50.9%, and 56.6% at 3, 6, and 12 months (p < 0.001), respectively, with marked improvement at three months and maintenance throughout follow‐up.Conclusions: Pemafibrate treatment significantly improved ALT levels and ALT normalization rates in MASLD patients with hypertriglyceridemia, with improvement observed at three months and a sustained effect up to 12 months. This is a large‐scale multicenter study to date evaluating pemafibrate in MASLD, providing robust evidence for its potential as a therapeutic option in this population.
Open AccessEffect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
Aim: Although pemafibrate, a selective peroxisome proliferator‐activated receptor α (PPARα) modulator primarily prescribed for hypertriglyceridemia, may improve liver function in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), its efficacy has not been sufficiently evaluated. This study aimed to assess the effect of pemafibrate on liver function in patients with MASLD using a nationwide multicenter cohort.Methods: In this nationwide multicenter study, we analyzed 352 patients diagnosed with MASLD and hypertriglyceridemia who newly initiated pemafibrate therapy. The primary outcome was the rate of ALT normalization (ALT ≤ 30 U/L). Laboratory data were collected at baseline and 3, 6, and 12 months after pemafibrate initiation, and longitudinal changes were evaluated.Results: The mean ALT levels decreased significantly from 60.1 ± 1.8 U/L at baseline to 44.9 ± 1.4, 41.6 ± 1.3, and 38.1 ± 1.3 U/L at 3, 6, and 12 months, respectively (all p < 0.001). The ALT normalization rate increased from 30.4% at baseline to 46.0%, 50.9%, and 56.6% at 3, 6, and 12 months (p < 0.001), respectively, with marked improvement at three months and maintenance throughout follow‐up.Conclusions: Pemafibrate treatment significantly improved ALT levels and ALT normalization rates in MASLD patients with hypertriglyceridemia, with improvement observed at three months and a sustained effect up to 12 months. This is a large‐scale multicenter study to date evaluating pemafibrate in MASLD, providing robust evidence for its potential as a therapeutic option in this population.